Founded as a privately held biotechnology company, ImmunGene is dedicated to the development of proprietary antibody-cytokine fusion technology and monoclonal antibody-based therapies. The company's core mission is to advance innovative treatments for cancer, autoimmune disorders, and other diseases. With a focus on drug discovery and development, ImmunGene offers a range of programs at various stages of development aimed at improving patient outcomes in these critical areas.
ImmunGene has garnered support from notable investors, including several biotechnology executives, and has received federal government grants such as the NIH-SBIR. The company's key achievements include the development of multiple therapeutic candidates that leverage their unique antibody-cytokine fusion technology. ImmunGene's impact is marked by its potential to revolutionize treatment paradigms for serious diseases, contributing significantly to the biotechnology landscape.
